Dopamine receptor agonists for protection and repair in Parkinson's disease

Current Topics in Medicinal Chemistry

Volumn 8, Issue 12, 2008, Pages 1089-1099

  Ferrari Toninelli, Giulia ^a   Binin, Sara A ^a   Cenini, Giovanna ^a   Maccarinelli, Giuseppina ^a   Grilli, Mariagrazia ^b   Uberti, Daniela ^a   Memo, Maurizio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Alzheimer's disease; Beta amyloid; Fibrils; Free radicals; Neurodegeneration; Neurogenesis; Neurotrophic factors; Oxidative stress; Parkinson's disease

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 3,4,4A,5,6,10B HEXAHYDRO 9 CARBAMOYL 4 PROPYL 2H NAPHTH[1,2 B] 1,4 OXAZINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMYLOID BETA PROTEIN; APOMORPHINE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; LEVODOPA; LY 741626; NAFADOTRIDE; NEUROTROPHIC FACTOR; PERGOLIDE; PRAMIPEXOLE; QUINPIROLE; RACLOPRIDE; ROPINIROLE; S 32504; S 32601; S 33084; SB 269652; SULPIRIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CELL VIABILITY; CONTINUOUS INFUSION; DEGENERATIVE DISEASE; DEMENTIA; DRUG BINDING; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; REVIEW; TREMOR;

EID: 52949119184     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608785161402     Document Type: Review

References (122)

1. Davie, C. A. A review of Parkinson's disease. Br. Med. Bull. 2008 [Epub ahead of print].
2. McKeith, I. G; Mosimann, U. P. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat. Disord. 2004, 10, S15-S18.
3. Adams, J. D.; Odunze, I. N. Oxygen free radicals and Parkinson's disease. Free Radic. Biol. Med. 1991, 10, 161-169.
4. Schapira, A. H. Neuroprotection in PD - A role for dopamine agonists? Neurology 2003, 61, S34-S42.
5. Jenner, P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr. Opin. Neurol. 2003, 16, S3-S7.
6. Olanow, C. W. A radical hypothesis for neurodegeneration. Trends Neurosci. 1993, 16, 439-444.
7. Ossowska, K.; Wardas, J.; Kuter, K.; Nowak, P.; Dabrowska, J.; Bortel, A.; Labus, L. Influence of paraquat on dopaminergic transporter in the rat brain. Pharmacol. Rep. 2005, 57, 330-335.
8. Miller, G. W. Paraquat the red herring of Parkinson's disease research. Toxicol. Sci. 2007 100, 1-2.
9. Shepherd, K. R.; Lee, E. S.; Schmued, L.; Jiao, Y.; Ali, S. F.; Oriaku, E. T.; Lamango, N. S.; Soliman, K. F.; Charlton, C. G. The potentiating effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Pharmacol. Biochem. Behav. 2006, 83, 349-359.
10. Lipton, S. A.; Rosenberg, P. A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330, 613-622.
11. Radad, K.; Gille, G.; Rausch, W. D. Short review on dopamine agonists, insight into clinical and research studies relevant to Parkinson's disease. Pharmacol. Rep. 2005, 57, 701-712.
12. Gould, E.; Gross, C. G. Neurogenesis in adult mammals, some progress and problems. Neurosci. 2002, 22, 619-623.
13. Lidow M. S.; Rakic, P. Neurotransmitter receptor in the proliferative one of the developing primate occipitale lobe. J. Comp. Neurol. 1995, 360, 393-402.
14. Hoglinger, G. U.; Rizk, P.; Muriel, M. P.; Duvkaerts, C.; Oertel, W.H.; Caille, I.; Hirsch, E.C. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 2004, 7, 726-735.
15. Freundlieb, N.; François, C.; Tandé, D.; Oertel, W.H.; Hirsch, E.C.; Höglinger G.U. Dopaminergic substantia nigra neurons project topographicall organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J. Neurosci. 2006, 26, 2321-2325.
16. Joyce, J.N.; Millan, M.J. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr. Opin. Pharmacol. 2007, 7, 100-105.
17. Van Kampen, J.M.; Hagg, T.; Robertson, H.A. Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur. J. Neurosci. 2004, 19, 2377-2387.
18. Van Kampen, J.M.; Eckman, C.B. Dopamine 63 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behaviour. Neurobiol. Dis. 2006, 26, 7272-7280.
19. Sayles, M.; Jain, M.; Barker, R.A. The cellular repair of the brain in Parkinson's disease-past, present and future. Transpl. Immunol. 2004, 12(3-4), 321-42.
20. Baker, S.A.; Baker, K.A.; Hagg, T. D3 dopamine receptors do not regulate neurogenesis in the subventricular zone of adult mice. Neurobiol. Dis. 2005, 18, 523-527.
21. Milosevic, J.; Schwarz, S.C.; Maisel, M.; Poppe-Wagner, M.; Dieterlen, M.T.; Storch, A.; Schwarz, J. Dopamine D2/D3 receptor stimulation fails to promote dopaminergic neurogenesis of murine and human midbrain-derived neural precursor cells in vitro. Stem Cells Dev. 2007.
22. Kippin, T.E.; Kapur, S.; van der Kooy, D. Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J. Neurosci. 2005, 25, 5815-5823.
23. Batelli, S.; Albani, D.; Rametta, R.; Polito, L.; Prato, F.; Pesaresi, M.; Negro, A.; Forloni, G. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress, relevance for Parkinson's disease and involvement of HSP70. PLoS ONE. 2008, 3(4), e1884.
24. Li, J.; Zhu, M.; Manning-Bog, A.B.; Di Monte, D.A.; Fink, A.L. Dopamine and L-dopa disaggregate amyloid fibrils, implications for Parkinson's and Alzheimer's disease. FASEB J. 2004, 18(9), 962-964.
25. Ono, K.; Hirohata, M.; Yamada, M. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. J. Neurosci. Res. 2007, 85(7), 1547-1557.
26. Elsworth, J.D.; Redmond, D.E.; Leranth, C.; Bjugstad, K.B.; Sladek, J.R.; Collier, T.J.; Foti, S.B.; Samulski, R.J.; Vives, K.P.; Roth, R.H. AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. Exp. Neurol. 2008 [Epub ahead of print].
27. Airaksinen, M.S.; Saarma, M. The GDNF family, signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3, 383-394.
28. Lin, L.F.; Doherty, D.H.; Lile, J.D.; Bektesh, S.; Collins, F. GDNF, a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260, 1130-1132.
29. Choi-Lundberg, D.L.; Bohn, M.C. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Brain Res. Dev. 1995, 85, 80-88.
30. Schaar, D.G.; Sieber, B.A.; Dreyfus, C.F.; Black, I.B. Regional and cell-specific expression of GDNF in rat brain, Exp. Neurol. 1993, 124, 368-371.
31. Stromberg, I.; Bjorklund, L.; Johansson, M.; Tomac, A.; Collins, F.; Olson, L.; Hoffer, B.; Humpel, C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. Neurol. 1993, 124, 401-412.
32. Ahn, Y.H.; Bensadoun, J.C.; Aebischer, P.; Zurn, A.D.; Seiger, A.; Bjorklund, A.; Lindvall, O.; Wahlberg, L.; Brundin, P.; Kaminski Schierle, G.S. Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor. Brain Res. Bull. 2005, 66, 135-142.
33. Espejo, M.; Cutillas, B.; Arenas, T.E.; Ambrosio, S. Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor. Cell Transplant. 2000, 9, 45-53.
34. Rosenblad, C.; Martinez-Serrano, A.; Bjorklund, A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996, 75, 979-985.
35. Sautter, J.; Tseng, J.L.; Braguglia, D.; Aebischer, P.; Spenger, C.; Seiler, R.W.; Widmer, H.R.; Zurn, A.D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts, Exp. Neurol. 1998, 149, 230-236.
36. Sinclair, S.R.; Svendsen, C.N.; Torres, E.M.; Martin, D.; Fawcett, J.W.; Dunnett, S.B. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. NeuroReport 1996, 7, 2547-2552.
37. Sullivan, A.M.; Pohl, J.; Blunt, S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease, Eur. J. Neurosci. 1998, 10, 3681-3688.
38. Wilby, M.J.; Sinclair, S.R.; Muir, E.M.; Zietlow, R.; Adcock, K.H.; Horellou, P.; Rogers, J.H.; Dunnett, S.B.; Fawcett, J.W. A glial cell line-derived neurotropic factor-secreting clone of the Schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra. J. Neurosci. 1999, 19, 2301-2312.
39. Altar, C.A.; Boylan, C.B.; Jackson, C.; Hershenson, S.; Miller, J.; Wiegand, S.J.; Lindsay, R.M.; Hyman, C. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. Sci. USA 1992, 89, 11347-11351.
40. Altar, A.; Boylan, C.B.; Fritsche, M.; Jones, B.E.; Jackson, C.; Wiegand, S.J.; Lindsay, R.M.; Hyman, C. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. J. Neurochem. 1994, 63, 1021-1032.
41. Hyman, C.; Hofer, M.; Barde, Y.A.; Juhasz, M.; Yancopoulos, G.D.; Squinto, S.P.; Lindsay, R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350, 230-232.
42. Levivier, M.; Przedborski, S.; Benesics, C.; Kang, U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneratiou of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 1995, 15, 7810-7820.
43. Yoshimoto, Y.; Lin, Q.; Collier, T.J.; Frim, D.M.; Breakefield, X.O.; Bohn, M.C. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res. 1995, 691, 25-36.
44. Klein, R.L.; Lewis, M.H.; Muzyczka, N.; Meyer, E.M. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. 1999, 847, 314-320.
45. Delcu, D.; Hanssens, Y.; Northway, M.G. Subcutaneous apomorphine, an evidence-based review of its use in Parkinson's disease. Drugs Aging. 2004, 2(11), 687-709.
46. Gassen, M.; Glinka, Y.; Pinchasi, B.; Youdim, M.B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 1996, 308(2), 219-225.
47. Liu, J.; Mori, A.; Ogata, K. Antioxidant and pro-oxidant assay for a new drug GEPC, detected by ESR spectrometry and by protective effects on lipid peroxidation and biomolecule degradation. Res. Commun. Chem. Pathol. Pharmacol. 1993, 82(2), 151-166.
48. 2and 6-hydroxydopamine. Mov. Disord. 1998, 13, 661-667.
49. Youdim, M.B.; Grünblatt, E.; Mandel, S. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. NY Acad. Sci. 1999, 890, 7-25.
50. Grünblatt, E.; Mandel, S.; Berkuzki, T.; Youdim, M.B. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 1999, 14(4), 612-618.
51. Battaglia, G.; Busceti, C.L.; Cuomo, L.; Giorgi, F.S.; Orzi, F.; De Blasi, A.; Nicoletti, F.; Ruggieri, S.; Fornai, F. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology 2002, 42(3), 367-373.
52. Yuan, H.; Sarre, S.; Ebinger, G.; Michotte, Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods. 2005, 144(1), 35-45.
53. Guo, H.; Tang, Z.; Yu, Y.; Xu, L.; Jin, G.; Zhou, J. Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur. J. Neurosci. 2002, 16(10), 1861-1870.
54. Sam, E.E.; Verbeke, N. Free radical scavenging properties of apomorphine enantiomers and dopamine, possible implication in their mechanism of action in parkinsonism. J. Neural Transm. Park. Dis. Dement Sect. 1995, 10(2-3), 115-127.
55. Ubeda, A.; Montesinos, C.; Payá, M.; Alcaraz, M.J. Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic. Biol. Med. 1993, 15(2), 159-167.
56. Roceri, M.; Molteni, R.; Fumagalli, F.; Racagni, G.; Gennarelli, M.; Corsini, G.; Maggio, R.; Riva, M. Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum. J. Neurochem. 2001, 76(4), 990-997.
57. Weinreb, O.; Mandel, S.; Youdim, M.B. Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin. Ann. N Y Acad. Sci. 2003, 993, 351-361.
58. Foley, P.; Gerlach, M.; Double, K.L.; Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm. 2004, 111, 1375-1446.
59. Watts, R.L. The role of dopamine agonists in early Parkinson's disease. Neurology 1997, 49, S34-S48.
60. Kondo, T.; Ito, T.; Sugita, Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann. NY Acad. Sci. 1994, 738, 222-229.
61. Ogawa, N.; Tanaka, K.; Asanuma, M.; Kawai, M.; Masumizu, T.; Kohno, M.; Mori, A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 1994, 657, 207-213.
62. Takashima, H.; Tsujihata, M.; Kishikawa, M.; Freed, W.J. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp. Neurol. 1999, 159, 98-104.
63. Yoshikawa, T.; Minamiyama, Y.; Naito, Y.; Kondo, M. Antioxidant properties of bromocriptine, a dopamine agonist. J. Neurochem. 1994, 62, 1034-1038.
64. Kihara, T.; Shimohama, S.; Sawada, H.; Honda, K.; Nakamizo T.; Kanki, R.; Yamashita, H.; Akaike, A. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J. Neurosci. Res. 2002, 70(3), 274-282.
65. Marvanova, A.; Nichols, M. Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHD. J. Mol. Neurosci. 2007, 31(2), 127-137.
66. Baseman, D.G.; O'Suilleabhain, P.E.; Reimold, S.C.; Laskar, S.R.; Baseman, J.G.; Dewey, R.B. Jr Pergolide use in Parkinson's disease is associated with cardiac valve regurgitation. Neurology 2004, 63, 301-304.
67. Horvath, J.; Fross, R.D., Kleiner-Fisman, G.; Lerch, R.; Stalder, H.; Liaudat, S.; Raskoff, W.J. Severe multivalvular heart disease, a new complication of the ergot derivative dopamine agonist. Mov. Disord. 2004, 19, 656-662.
68. Van Camp, G.; Flamez, A.; Cosyns, B.; Weytjens, C.; Muyldermans, L.; Van Zandijcke, M.; De Sutter, J. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004, 363, 1179-1183.
69. Felten, D.L.; Felten, S.Y.; Fuller, R.W.; Romano, T.D.; Smalstig, E.B.; Wong, D.T.; Clemens, J.A. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol. Aging 1992, 13, 339-351.
70. Asanuma, M.; Ogawa, N.; Nishibayashi, S.; Kawai, M.; Kondo, Y.; Iwata, E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch. Int. Pharmacodyn. Ther. 1995, 329, 221-230.
71. Gill, G.; Rausch, W.D.; Hung, S.T.; Moldzio, R.; Janetzky, B.; Hundemer, H.P.; Kolter, T.; Reichmann, H. Pergolide protects dopaminergic neurons in primary culture under stress conditions. J. Neural Transm. 2002, 109, 633-643.
72. Gomez-Vargas, M.; Nishibayashi-Asanuma, S.; Asanuma, M.; Kondo,Y.; Iwata, E.; Ogawa, N. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 1998, 790, 202-208.
73. Opacka-Juffry, J.; Wilson, A.W.; Blunt, S.B. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res. 1998, 810, 27-33.
74. Uberti, D.; Carsana, T.; Francisconi, S.; Toninelli, G.F.; Canonico, P.L.; Memo, M. A novel mechanism for pergolide-induced neuroprotection, inhibition of NFkappaB nuclear translocation. Biochem. Pharmacol. 2004, 67, 1743-1750.
75. Schwarz, J. Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Curr. Opin. Neurol. 2003, 16, Suppl 1, S27-S33.
76. Uberti, D.; Piccioni, L.; Colzi, A.; Bravi, D.; Canonico, P.L.; Memo, M. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur. J. Pharmacol. 2002, 434, 17-20.
77. Grilli, M.; Memo, M. Possible role of NF-kappaB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Cell Death Differ. 1999, 6, 22-7.
78. Grilli, M.; Memo, M. Nuclear factor-kappaB/Rel proteins, a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem. Pharmacol. 1999, 57, 1-7.
79. Cheer, S.M.; Bang, L.M.; Keating, G.M. Ropinirole, for the treatment of restless legs syndrome. CNS Drugs 2004, 18, 747-754.
80. Eden, R.J.; Costall, B.; Domeney, A.M.; Gerrard, P.A.; Harvey, C.A.; Kelly, M.E.; Naylor, R.J.; Owen, D.A.; Wright, A. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav. 1991, 38, 147-154.
81. Clarke, C.E.; Deane, K.H. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. 2001, CD001517.
82. Schrag, A.; Keens, J.; Warner, J. Ropinirole for the treatment of tremor in early Parkinson's disease. Eur. J. Neurol. 2002, 9, 253-257.
83. Allen, R.; Becker, P.M.;:BOgan, R.; Schmidt, M.; Kushida, C.A.; Fry, J.M.; Poceta.: J.S.; Winslow, D. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004, 27, 907-914.
84. Iida, M.; Miyazaki, I.; Tanaka, K.; Kabuto, H.; Iwata-Ichikawa, E.; Ogawa, N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999, 838, 51-59.
85. Tanaka, K.; Miyazaki, I.; Fujita, N.; Haque, M.E.; Asanuma, M.; Ogawa, N. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem. Res. 2001, 26, 31-36.
86. Whone, A.L.; Watts, R.L.; Stoessl, A.J.; Davis, M.; Reske, S.; Nahmias, C.; Lang, A.E. Rascol, O.; Ribeiro, M.J.; Remy, P.; Poewe, W.H.; Hauser, R.A.; Brooks, D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa, the REALPET study. Ann. Neurol. 2003, 54, 93-101.
87. Du, F.; Li, R.; Huang, Y.; Li, X. and Le, W. Dopamine D3 receptor-preferring a agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 2005, 22, 2422-2430.
88. Sheng, C.; Xiaojie, Z.; Dehua, Y.; Yunlan, D.; Liang, L.; Xuping, L.; Ming, M.; Weidong, L. D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dapendent pathways. FEBS Lett. 2008, 582, 603-610.
89. Junn, E.; Mouradian, M.M. Apoptotic signaling in dopamine induced cell death, the role of oxidative stress, P38 mitogen-activated protein kinase, cytochrome c and caspases. J. Neurochem. 2001, 78, 374-383.
90. Davis, R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103, 239-252.
91. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R.J. and Greenberg, M.E. Opposing effects of ERK and JNK-P38 MAP kinases on apoptosis. Science 1995, 270, 1326-1331.
92. Li, P.; Nijhawan, D.; Budihardjo, I.; Stinivasula, S.M.; Ahmad, M.; Alnemri, E.S. and Wang, X. Cytochrome c and dATPdependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 2004, 91, 419-489.
93. Consales, C.; Volpicelli, F.; Greco, D.; Leone, L.; Colucci-D'Amato, L.; Perrone-Capano, C.; Di Porzio, U. GDNF signaling in embryonic midbrain neurons in vitro. Brain Res. 2007, 1159, 28-39.
94. Le, W.D.; Jankovic, J.; Xie, W.; Appel, S.H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J. Neural. Transm. 2000, 107, 1165-1173.
95. Fujita, Y.; Izawa, Y.; Ali, N.; Kanematsu, Y.; Tsuchiya, K.; Hamano, S.; Tamaki, T.; Yoshizumi, M. Pramipexole protects against H202-induced PC12 cell death. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 372, 257-266.
96. Uberti, D.; Bianchi, I.; Olivari, L.; Ferrari-Toninelli, G.; Canonico, P.; Memo, M. Neuroprotective effect of pramipexole against beta amyloid toxicity depends on peptide aggregated states. Eur. J. Pharmacol. 2007, 569(3), 194-196.
97. Pattee, G.L.; Post, G.R.; Gerber, R.E.; Bennett, J.P. Jr. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003, 4, 90-95.
98. Presgraves, S.P.; Ahmed, T.; Borwege, S.; Joyce, J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 2004, 5(8), 579-598.
99. Presgraves, S.P.; Borwege, S.; Millan, M.J.; Joyce, J.N. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinum in terminally differentiated SH-SY5Y cells. Exp. Neurol. 2004, 190(1), 157-170.
100. Moreira, P.I.; Smith, M.A.; Zhu, X.; Honda, K.; Lee, H.G.; Aliev, G.; Perry, G. Oxidative damage and Alzheimer's disease, are antioxidant therapies useful? Drug News Perspect. 2005, 18, 13-19.
101. Behl, C. Oxidative stress in Alzheimer's disease, implications for prevention and therapy. Subcell. Biochem. 2005, 38, 65-78.
102. Aksenov, M.Y.; Aksenova M.V.; Carney, J.M.; Butterfield, D.A. Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radic. Res. 1997, 27, 267-281.
103. Butterfield, D.A. Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain, mechanisms and consequences. Curr. Med, Chem. 2003, 10, 2651-2658.
104. Lin, M.T.; Beal, F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787-795.
105. Barnham, K.J.; Masters, C.L.; Bush, A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3, 205-214.
106. Zhang, Y.W.; Xu, H. Molecular and cellular mechanisms for Alzheimer's disease, understanding APP metabolism. Curr. Mol. Med. 2007, 7(7), 687-696.
107. Bredesen, D.E.; Rabizadeh, S. APP-based neuroprotective strategies. Curr. Alzheimer Res. 2007, 4(5),541-543.
108. Butterfield, D.A. beta-Amyloid-associated free radical oxidative stress and neurotoxicity, implications for Alzheimer's disease. Chem. Res. Toxicol. 1997, 10, 495-506.
109. Walsh, D.M.; Klyubin, I.; Shankar, G.M.; Townsend, M., Fadeeva, J.V.; Betts, V.; Podlisny, M.B.; Cleary, J.P.; Ashe, K.H.; Rowan, M.J.; Selkoe, D.J. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 2005, 33(Pt 5), 1087-1090.
110. Walsh, D.M.; Selkoe, D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101(5), 1172-1184.
111. Abramova, N.A.; Cassarino, D.S.; Khan, S.M.; Painter, T.W.; Bennett, J.P. Jr. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J. Neurosci. Res. 2002, 67, 494-500.
112. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 2002, 287, 1653-1661.
113. No authors listed. A randomized controlled, trial comparing pramipexole with levodopa in early Parkinson's disease, design and methods of the, CALM-PD Study. Clin. Neuropharmacol. 2000, 23(1), 34-44.
114. Rakshi, J.S,; Pavese, N.; Uema, T.; Ito, K.; Morrish, P.K.; Bailey, D.L.; Brooks, D.J. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa, an 18F-dopa PET study. J. Neural Transm. 2002, 109(12), 1433-1443.
115. Linazasoro, G.; Obeso, J.A.; Gómez, J.C.; Martínez, M.; Antonini, A.; Leenders, K.L. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease, an in vivo study by PET. Clin. Neuropharmacol. 1999, 22(5), 277-280.
116. Morrish, P.K. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov. Disord. 2003, Suppl 7, S63-S70.
117. Marek, K.; Jennings, D.; Seibyl, J. Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur. J. Neurol. 2002, Suppl.3, 15-22.
118. Burn, D.J.; McKeith, I.G. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Movement Disorders 2003, 18, 72-79.
119. Liberini, P.; Valerio, A.; Memo, M.; Spano,, P.F. Lewy-body dementia and responsiveness to cholinesterase inhibitors, a paradigm for heterogeneity of Alzheimer's disease? Trends Pharmacol Sci. 1996, 17(4), 155-160.
120. Ivan, C.S.; Seshadri, S.; Beiser, A. Dementia after stroke, the Framingham Study. Stroke 2004, 35, 1264-1268.
121. De la Torre, J.C. Is Alzheimer?s disease a neurodegenerative or a vascular disorder? Data, dogma and dialetics. Lancet Neurol. 2002, 3, 184-190.
122. Hayden, K.M.; Zandi, P.P.; Lyketsos, C.G;; Khachaturian, A.S. Vascular risk factors for incident Alzheimer's disease and vascular dementia, the Cache County study. Alzheimer Dis. Assoc. Disord. 2006, 127, 138-147.